S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Accelerate Diagnostics (AXDX) Stock Forecast, Price & News

-0.02 (-3.55%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
654,795 shs
Average Volume
447,188 shs
Market Capitalization
$37.87 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Accelerate Diagnostics logo

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.


See More Headlines

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$11.78 million
Book Value
($0.82) per share


Net Income
$-77.70 million
Net Margins
Pretax Margin




Free Float
Market Cap
$37.87 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.34 out of 5 stars

Medical Sector

242nd out of 1,420 stocks

Analytical Instruments Industry

9th out of 32 stocks

Analyst Opinion: 3.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

Is Accelerate Diagnostics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Accelerate Diagnostics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXDX, but not buy additional shares or sell existing shares.
View analyst ratings for Accelerate Diagnostics
or view top-rated stocks.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Accelerate Diagnostics

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings results on Monday, May, 16th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.09. During the same quarter in the previous year, the business earned ($0.41) earnings per share.
View Accelerate Diagnostics' earnings history

What price target have analysts set for AXDX?

2 analysts have issued twelve-month target prices for Accelerate Diagnostics' stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Accelerate Diagnostics' share price to reach $1.00 in the next twelve months. This suggests a possible upside of 83.9% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Accelerate Diagnostics' key executives?
Accelerate Diagnostics' management team includes the following people:
  • Mr. Jack Phillips, CEO, Pres & Director (Age 56, Pay $703.01k) (LinkedIn Profile)
  • Mr. Steve Reichling, Chief Financial Officer (Age 44, Pay $340k) (LinkedIn Profile)
  • Mr. Ron Price, Chief Commercial Officer of Americas (Age 58, Pay $240k) (LinkedIn Profile)
  • Laura Pierson, Investor Relations Officer
  • Mr. Michael Bridge, Sr. VP, Gen. Counsel & Sec.
  • Ms. Gretchen Strohminger, Sr. VP and Head of HR & Culture
  • Mr. Cherif Bousselham, Sr. VP & Head of Sales - EMEA
  • Ms. Laura Costa, Sr. VP & Head of Global Customer Support
  • Mr. John Meduri, Chief Strategy Officer
  • Dr. Lawrence Mertz, Sr. VP and Head of R&D
What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.31%), Baird Financial Group Inc. (2.50%), Griffin Asset Management Inc. (2.16%), Vanguard Group Inc. (1.90%), State Street Corp (1.77%) and Cladis Investment Advisory LLC (0.81%). Company insiders that own Accelerate Diagnostics stock include Hany Massarany, Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics

Which institutional investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Northern Trust Corp, BlackRock Inc., Group One Trading L.P., and Simplex Trading LLC. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Jack Phillips, Ron Price, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying Accelerate Diagnostics stock?

AXDX stock was bought by a variety of institutional investors in the last quarter, including Griffin Asset Management Inc., Baird Financial Group Inc., Cladis Investment Advisory LLC, State Street Corp, GSA Capital Partners LLP, JPMorgan Chase & Co., Goldman Sachs Group Inc., and Allworth Financial LP. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Hany Massarany, and Jack W Schuler.
View insider buying and selling activity for Accelerate Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $0.54.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics has a market capitalization of $37.87 million and generates $11.78 million in revenue each year. The medical research company earns $-77.70 million in net income (profit) each year or ($1.060010) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

Accelerate Diagnostics employs 220 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at (520) 365-3100, via email at [email protected], or via fax at 520-269-6580.

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.